China National Medicines Corporation Ltd. (SHA:600511)
China
· Delayed Price · Currency is CNY 30.02
+0.02 (0.07%)
At close: Mar 9, 2026
SHA:600511 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 22,635 | 25,819 | 21,594 | 21,051 | 23,789 | 37,205 | Upgrade
|
| Market Cap Growth | -5.87% | 19.57% | 2.58% | -11.51% | -36.06% | 80.69% | Upgrade
|
| Enterprise Value | 17,448 | 20,034 | 15,889 | 16,871 | 19,902 | 34,465 | Upgrade
|
| Last Close Price | 30.00 | 33.30 | 27.14 | 25.91 | 28.55 | 43.93 | Upgrade
|
| PE Ratio | 11.25 | 12.91 | 10.06 | 10.72 | 13.56 | 26.91 | Upgrade
|
| Forward PE | 10.70 | 10.71 | 8.91 | 10.01 | 12.87 | 19.84 | Upgrade
|
| PS Ratio | 0.44 | 0.51 | 0.44 | 0.46 | 0.51 | 0.92 | Upgrade
|
| PB Ratio | 1.14 | 1.36 | 1.23 | 1.33 | 1.66 | 2.84 | Upgrade
|
| P/TBV Ratio | 1.29 | 1.55 | 1.41 | 1.53 | 1.93 | 3.39 | Upgrade
|
| P/FCF Ratio | 39.86 | 16.89 | 8.37 | 9.29 | 12.77 | 30.18 | Upgrade
|
| P/OCF Ratio | 35.45 | 15.56 | 7.92 | 8.79 | 12.15 | 28.58 | Upgrade
|
| PEG Ratio | 5.35 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | Upgrade
|
| EV/Sales Ratio | 0.34 | 0.40 | 0.32 | 0.37 | 0.43 | 0.85 | Upgrade
|
| EV/EBITDA Ratio | 7.84 | 9.05 | 6.39 | 6.96 | 9.24 | 20.65 | Upgrade
|
| EV/EBIT Ratio | 8.74 | 9.52 | 6.70 | 7.28 | 9.69 | 22.01 | Upgrade
|
| EV/FCF Ratio | 30.72 | 13.11 | 6.16 | 7.45 | 10.69 | 27.96 | Upgrade
|
| Debt / Equity Ratio | 0.03 | 0.05 | 0.03 | 0.03 | 0.05 | 0.06 | Upgrade
|
| Debt / EBITDA Ratio | 0.29 | 0.36 | 0.21 | 0.21 | 0.31 | 0.46 | Upgrade
|
| Debt / FCF Ratio | 1.15 | 0.55 | 0.21 | 0.23 | 0.38 | 0.65 | Upgrade
|
| Net Debt / Equity Ratio | -0.35 | -0.53 | -0.59 | -0.53 | -0.46 | -0.41 | Upgrade
|
| Net Debt / EBITDA Ratio | -3.36 | -4.53 | -4.18 | -3.46 | -3.07 | -3.25 | Upgrade
|
| Net Debt / FCF Ratio | -12.46 | -6.57 | -4.02 | -3.70 | -3.55 | -4.40 | Upgrade
|
| Asset Turnover | 1.50 | 1.50 | 1.60 | 1.58 | 1.76 | 1.65 | Upgrade
|
| Inventory Turnover | 9.31 | 10.54 | 11.90 | 11.53 | 13.05 | 11.63 | Upgrade
|
| Quick Ratio | 1.77 | 1.68 | 1.73 | 1.71 | 1.63 | 1.68 | Upgrade
|
| Current Ratio | 2.15 | 2.04 | 2.04 | 2.02 | 1.93 | 1.97 | Upgrade
|
| Return on Equity (ROE) | 11.00% | 11.67% | 13.98% | 14.09% | 14.05% | 11.95% | Upgrade
|
| Return on Assets (ROA) | 3.59% | 3.90% | 4.78% | 5.03% | 4.85% | 3.99% | Upgrade
|
| Return on Invested Capital (ROIC) | 13.09% | 21.00% | 25.82% | 24.13% | 21.03% | 16.79% | Upgrade
|
| Return on Capital Employed (ROCE) | 9.50% | 10.50% | 12.80% | 13.70% | 13.50% | 11.50% | Upgrade
|
| Earnings Yield | 8.88% | 7.75% | 9.94% | 9.33% | 7.37% | 3.72% | Upgrade
|
| FCF Yield | 2.51% | 5.92% | 11.96% | 10.76% | 7.83% | 3.31% | Upgrade
|
| Dividend Yield | 2.67% | 2.40% | 3.15% | 3.02% | 2.45% | 1.25% | Upgrade
|
| Payout Ratio | 28.53% | 34.12% | 33.06% | 31.16% | 36.36% | 44.34% | Upgrade
|
| Buyback Yield / Dilution | 0.00% | -0.00% | 0.00% | 0.00% | -0.00% | 0.98% | Upgrade
|
| Total Shareholder Return | 2.67% | 2.40% | 3.15% | 3.02% | 2.45% | 2.23% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.